To describe the effectiveness and safety of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis presenting features associated with clinical complexity.
Approach:
Case Series Description: A series of six clinical cases detailing baseline characteristics, treatment history, and outcomes of patients treated with tildrakizumab 200 mg.
Key Findings:
Most patients achieved PASI90 or PASI100 responses within 4–12 weeks.
Complete clearance (PASI100) was observed in four out of six patients.
Treatment effectiveness was maintained over approximately 24 months in most cases.
Tildrakizumab demonstrated a favorable safety profile.
Interpretation:
Tildrakizumab 200 mg was associated with high effectiveness and sustained clinical responses in patients with moderate-to-severe psoriasis characterized by high disease burden and multiple comorbidities.
Limitations:
Small sample size of six patients.
Real-world evidence may not be generalizable.
Conclusion:
The findings suggest that tildrakizumab 200 mg may be effective for managing complex psoriasis in patients with significant comorbidities.
Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.
